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CRISPR-Cas9 is a promising technology for gene therapy. However, the ON-target geno-
toxicity of CRISPR-Cas9 nuclease due to DNA double-strand breaks has received little
attention and is probably underestimated. Here we report that genome editing targeting
globin genes induces megabase-scale losses of heterozygosity (LOH) from the globin
CRISPR-Cas9 cut-site to the telomere (5.2Mb). In established lines, CRISPR-Cas9 nuclease
induces frequent terminal chromosome 11p truncations and rare copy-neutral LOH. In primary
hematopoietic progenitor/stem cells, we detect 1.1% of clones (7/648) with acquired
megabase LOH induced by CRISPR-Cas9. In-depth analysis by SNP-array reveals the pre-
sence of copy-neutral LOH. This leads to 11p15.5 partial uniparental disomy, comprising two
Chr11p15.5 imprinting centers (H19/IGF2:IG-DMR/IC1 and KCNQ1OT1:TSS-DMR/IC2) and
impacting H19 and IGF2 expression. While this genotoxicity is a safety concern for CRISPR
clinical trials, it is also an opportunity to model copy-neutral-LOH for genetic diseases and
cancers.
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1 provided evidences of engineered nuclea-
ses interest for the induction of double-strand break (DSB) in
order to be applied to the treatment of human diseases.
CRISPR-Cas9 has become a universal and powerful method for the
precise genome editing of many organisms2,3 to model diseases,
study genotype-phenotype relationships and improve gene therapy.
The modification of human hematopoietic stem/progenitor cells
(HSPCs) by CRISPR-Cas9 has rapidly led to clinical trials (clinical
trial.gov: NCT03655678/NCT03745287). However, nuclease-
mediated DSBs might present drawbacks as previously described
with I-Sce1, ZFN and TALEN4. Unwanted OFF-target effects have
been widely described. While DNA-DSBs can lead to undesirable
small insertions/deletions (Indels) and even chromosomal rear-
rangements (translocations, inversions and deletions)5–7, guide-
RNA (gRNA) design optimization and the use of highly specific
Cas9 nucleases can control them. However, safety issues regarding
genome ON-target integrity lack in-depth exploration. In addition
to small Indels, a single ON-target DSB can lead to large deletions
up to several kilobases in size, symmetrical or not, in mouse
embryos8,9, in mouse hematopoietic progenitors, in human
immortalized differentiated cells10 and human embryos11. Recently,
we reported that CRISPR-Cas9 can even cause megabase-scale
chromosomal truncations targeting Chromosome 10q (Chr10q) in
two human cell lines and in human primary fibroblasts deficient for
the tumor suppressor p5312. These large mono-allelic genomic
deletions were confirmed in human colorectal carcinoma HCT116
cells targeting Chr18q arm terminal deletion13, in human primary
iPSC targeting Chr7 and Chr2114, and very recently in early human
embryos with risk of aneuploidy14,15. In addition, more complex
rearrangements were present8,10–12, suggesting that the diversity of
potential deletion outcomes is vast. These genomic alterations
have not been reported until now because standard genotyping
methods frequently miss them. Reassuringly, to date these genomic
rearrangements have not been linked to deleterious consequences
for patients.
It is currently unknown whether large alterations can occur after
DSB in human HSPCs, the relevant clinical target cells for gene
therapy protocols. Indeed, HSPCs benefit from superior p53-
dependent capacity to prevent the accumulation of genetic lesions,
repair them, and avoid their propagation to daughter cells16–18.
In this work we observe that CRISPR-Cas9 nuclease induces
frequent terminal chromosome 11p truncations in cell line and rare
extra-large terminal copy-neutral loss-of-heterozygosity in HSPCs
resulting in partial uniparental disomy of the 11p15.4-11p15.5
imprinted region altering H19 and IGF2 gene expression.
Results
Globin gene targeting induces extra-large Chr11p LOH by
chromosomal terminal deletions in HEK cells. As we already
reported truncations on Chr10q by targeting UROS12, we first
evaluated whether such an event also occurs on Chr11p when
targeting the globin genes- in HEK293T cells. These cells are known
to have low p53 activity, a favorable condition not only for
editing17,18 but also for genomic instability. We designed three
gRNA sets (Fig. 1a). The first one (protocol #1) targets the sixth
codon of wild type HBB, which is mutated in sickle-cell disease
(green lightning). The two other sets (protocols #219 (blue light-
ning) and #320 (black lightning)) are related to those previously
published in successful preclinical studies for β-hemoglobinopathies
gene therapy. CRISPR-Cas9 targeting by protocols #2 and #3
increases hemoglobin F (HbF) synthesis, recapitulating the heredi-
tary persistence of fetal hemoglobin (HPFH)-associated mutations.
Protocol #2 targets a 13-nt sequence present in the promoters of the
HBG1 and HBG2 genes19. Protocol #3 uses 2 gRNAs to disrupt a
13.6 kb genomic region encompassing the δ- and β-globin genes
and a putative γ-δ intergenic HbF silencer20 (Fig. 1a). We trans-
fected each gRNA set with the ribonucleoprotein (RNP) Cas9
nuclease. After transfection, ICE (Inference of CRISPR Edits) ana-
lysis of the Sanger sequences confirmed the presence of a high rate
of indels with all gRNAs (83%, 63%, and 60% for #1, #2 and
#3, respectively). To evaluate Chr11p arm genomic integrity,
we first performed fluorescent in situ hybridization (FISH) on
HEK293T cells 4 days after editing (mainly trisomic for Chr11). We
used a Chr11-specific orange sub-centromeric probe (O) and a
Chr11p-specific sub-telomeric green probe (G) at 5.2Mb from the
globin cluster. Blind deep FISH analysis by an automated system
revealed that the cells displaying a 3O/2G profile increased from
7.3% (before transfection) to 17.2%, 11.9%, 20.8% after protocols
#1, #2 and #3, respectively (Fig. 1b day 4 and Supplementary
Figs. 1–3, >550 cells per condition). At the same time, Chr11 2O/3G
cell percentages and FISH analysis of another chromosome (Chr2)
to monitor technical noise were low and stable (around 1% in all
conditions) (Fig. 1b and Supplementary Fig. 4). Around 5% of cells
were disomic for Chr11 in control cells and the prevalence was
stable in edited cells, which is not in favor of induced loss of the
entire chromosome. Finally, targeting another chromosome
(Chr10) with nuclease did not impact 3O/2G Chr11-cell percen-
tages, indicating that Chr11-specific sub-telomeric probe hybridi-
zation loss increases at day 4 were specific genetic outcomes due to
Cas9 nuclease use in Chr11p (Fig. 1c, left). Regardless of the gRNAs
and the protocols, higher frequencies of unbalance in Chr11p copies
suggested that these events were likely independent of the location
or the number of DSBs. Sub-telomeric green probe losses were less
frequent in protocols #1 and #3 at D18, but still persisted even after
numerous cell divisions (at around 10% in all conditions without
significant difference between protocols, p= 0.838 two-sided Chi-
square tests) and was significantly higher than in unedited cells
(NT, non-transfected: 6.2%) (Fig. 1b right, day 18). In contrast,
Chr2 DNA FISH at day 18 showed stability of this chromosome
(Supplementary Fig. 4). These sub-telomeric probe losses could
be consistent with extra-large terminal deletions of Chr11 (5.2Mb)
downstream of the globin locus, induced by nuclease-mediated
DSB.
To confirm this hypothesis and estimate the incidence of these
outcomes, we carried out cellular subcloning and picked up 203
clones (54, 64, 54, 31 from control and protocols #1-2-3,
respectively, Fig. 2a). To detect megabase deletions, we screened
for homozygosity two single-nucleotide polymorphisms (SNP,
rs2735691/rs10835611) in RRM1, heterozygous before editing
and located 1.1 Mb telomeric from the Cas9 breakpoint. While
only 1.9% (1/54) of cells lost RRM1 SNP heterozygosity in the
control cells, 20.3% (13/64), 18.5% (10/54) and 25.8% (8/31) of
clones exhibited LOH in protocols #1 to #3, respectively, without
significant difference between the protocols (Fig. 2a). 25/27 of the
clones with RRM1 SNP LOH (92.6%) screened by FISH lost one
sub-telomeric green probe (3O/2G) in favor of a Chr11p terminal
deletion (Fig. 2b and Supplementary Table 1). Array-CGH (Array
Comparative Genomic Hybridization) identified the location of
the globin genes targeted by CRISPR-Cas9 as the start of the
breakpoint delimiting this 5.2-megabase terminal deletion
in HEK293T cells and confirmed these terminal deletions,
whatever the protocol used (Fig. 2b). Interestingly, 2/27 clones
(7.4% of RRM1 LOH clones) kept 3O/3G signals, suggesting a
copy-neutral LOH by mitotic recombination confirmed by CGH-
array (Fig. 2b and Supplementary Table 1).
To conclude, in HEK293T cells, CRISPR-Cas9 nuclease
induced frequent terminal Chr11p truncations and rare copy-
neutral LOH.
None of the top-10-predicted off-target sites were situated on
Chr11 (Supplementary Table 2), suggesting that these genetic
outcomes were not due to additional off-target cut in the Chr11p.
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To clarify this prediction, we used HiFi Cas9, which is known to
drastically reduce off-target cuts. HiFi Cas9 also increased the
frequency of loss of the sub-telomeric probe, confirming that
these chromosomal rearrangements were not caused by off-target
effects (Fig. 1c right). Frequency of 3G/2O cells with HiFi was
twofold lower compared to protocol #3 using regular Cas9 but
with a cut-off efficiency also reduced by half (in our experiment,
31% of indels with HiFi versus 61% with wild type Cas9). Taken
together these data demonstrate that induced LOH are not
dependent to off-target activity of Cas9 nuclease.
CRISPR-Cas9-mediated globin gene targeting can induce
extra-large Chr11p CN-LOH in human hematopoietic stem/
progenitor cells (HSPCs). We then investigated whether these
putative side-effects occurred in the clinically relevant HSPCs
using CD34+ cord-blood cells. We repeated protocols #1 and #3
in diploid HSPCs by inducing one or two cuts, respectively
(Fig. 3a). FISH analyses at D18 revealed slight increases in 2O/1G
cells with both protocols in both experiments (+1.3% and
+3.55% for #1 and #3, respectively, versus non-transfected (NT)





























































































by RRM1 SNP 
sequencing
Quantitative FISH
(day 4 and/or day 18) 
Subclonal 













p=0.0025 p <0.0001 p=0.016 p=0.017 p=0.020
p <0.0001 p <0.0001
p=0.37
p <0.0001 p <0.0001 p <0.0001
p=0.003
p <0.0001
Chi-square tests: Chi-square tests :
Chi-square tests : Chi-square tests :
NATURE COMMUNICATIONS | https://doi.org/10.1038/s41467-021-25190-6 ARTICLE
NATURE COMMUNICATIONS |         (2021) 12:4922 | https://doi.org/10.1038/s41467-021-25190-6 | www.nature.com/naturecommunications 3
Fig. 3b, Supplementary Table 3, Supplementary Figs. 5 and 6).
Chr11 1O/2G and Chr2 2G/1O cell percentages (Fig. 3b, c) did
not increase. On the contrary, green probe losses (2O/1G) were
suggestive of 11p terminal deletions, but the high background
noise of 2O/1G in non-transduced cells makes the analysis
complicated and international cytogenetic guidelines consider
that the increase must be greater than 5% to be considered
significant21. To improve sensitivity and conclude, we subcloned
HSPCs by FACS cell sorting at day 4 post-editing. We first
screened LOH in CD34+ clones by analyzing 4 SNPs in RRM1
and CARS1 loci, 1.1 and 2.2 Mb telomeric to the globin cluster.
We did not find any SNP loss in subclones after protocol #1 but
we were able to analyze only 79 clones and guide RNA activity
was low (indel rate: 10%). As LOHs seem to be DSB frequency-
dependent, we chose protocol #3 for extensive cloning experi-
ments. We performed two independent experiments of protocol
#3 (indel rates of 86 and 88%), revealing the presence of two
clones that lost one allele of the four SNPs (1/104, 1/107, in #3.1,
#3.2, respectively, Fig. 3d, f). To be sure that these results were not
due to the use of valproic acid (VPA, which improves CD34+ cell
subcloning) and AMAXA nucleofector enhancer (enh, recom-
mended by the manufacturer to increase editing efficiency), the
same experiments were performed without VPA (VPA−/enh+)
or the enh (VPA+/enh−). Clonal analysis revealed the presence
of one clone with RRM1 SNPs losses (at 1.1 Mb from the cut-site)
and KCNQ1 SNP loss (at 2.5 Mb from the cut-site), in the VPA
−/enh+ condition (1/41 clones). The frequency of LOH was
similar to that of the control VPA+/enh+ (1/50 clones) (Fig. 4a,
b, c). We did not find any LOH clones in VPA+/enh− condition
(0/47 clones). Therefore, we removed both VPA and enh and
increased the number of analyzed clones to establish whether the
presence of LOH was dependent on enh. We obtained 3/299
colony-forming cells (CFC) with LOH including RRM1 and
KCNQ1 loci (Fig. 4a, c), confirming the absence of VPA and enh
bias. Taken together, in primary hematopoietic progenitor/stem
cells, we detected 1.1% of clones (7/648) with acquired megabase
LOH induced by CRISPR-Cas9.
For two clones (34.8 and 34.15) we have the chance to have
enough material to explore in-depth these LOH induced by
CRISPR-Cas9. Unexpectedly, array-CGH did not show any loss of
genomic material (Fig. 3e), suggesting that these megabase-scale
LOH were not due to terminal chromosomal deletions but to the
occurrence of a copy-neutral loss of heterozygosity (CN-LOH),
also called partial uniparental disomy. CGH/SNP-array analysis
validated this hypothesis and mapped a single specific induced CN-
LOH (iCN-LOH) in both clones spanning 5.2Mb from the globin
gene cut to the telomere (Fig. 5a and Supplementary Fig 7). Sanger
sequencing of SNPs along the Chr11p arm again confirmed these
unexpected extra-large CN-LOH in primary hematopoietic cells
probably due to mitotic recombination (Supplementary Fig. 8). To
more precisely map the start of LOH, we carried out Sanger
sequencing of the breakpoint of the two clones. Clone 34.15
analysis revealed a homozygous 4-base pairs deletion, suggesting
that the CN-LOH starts exactly at the CRISPR-Cas9-cut-site. Two
different edited alleles were present in clone 34.8, suggesting that
CN-LOH starts between the cut-site and the first probe of the SNP
array at 0.4Mb (Supplementary Fig. 9a). We chose additional SNPs
nearer to the CRISPR cut-site and sequenced them. We found an
additional SNP (not studied by SNP array) located 0.18Mb from
the cut-site on the telomeric side. It became homozygous in the
two CD34 clones, demonstrating that the LOH is already present.
As expected, the SNP on the centromeric side (0.06Mb from the
globin cut-site) were still heterozygous (supplementary Fig. 9b).
Taken together, these data highlight the presence of CN-LOH
induced by CRISPR-Cas9 in HSPC starting in the surroundings of
the DSB.
Functional consequences of iCN-LOH. As the 11p15.4-11p15.5
locus is subjected to parental genomic imprinting22, we analyzed
the methylation status of H19 (a non-coding RNA tumor sup-
pressor with maternal expression), IGF2-AS (insulin-like growth
factor II gene, pro-oncogenic gene expressed only from the
paternal allele) and the KCNQ1OT1 imprinting centers in three
LOH-positive clones compared to five LOH-negative clones.
Normal cells harbor both unmethylated and methylated alleles of
the H19, IGF2-AS and KCNQ1OT1 regions from paternal and
maternal alleles (Fig. 5b, c and Supplementary Fig. 10). Some
HSPC clones (34.8 and 34.15) with CN-LOH exhibited bi-allelic
methylation of the H19 Differentially Methylated Region (DMR)/
proximal promoter and the IGF2-AS DMR imprinting centers,
and a bi-allelically unmethylated KCN1QOT1 locus, indicative of
partial paternal uniparental disomy impacting these imprinting
centers. One other HSPC LOH-clone (34.40) showed an opposite
imprinting profile indicative a partial maternal uniparental dis-
omy showing that both profiles are possible without parental bias
in vitro (Fig. 5b, c and Supplementary Fig. 10). Taken together,
based on the haplotype, we obtained seven clones including three
paternal duplications (34.8, 34.15, and 34.37) and four maternal
duplications (34.38; 34.40; 34.175 and 34.190). We then evaluated
the transcriptional modifications due to abnormal methylations
in two LOH clones with partial paternal uniparental disomy (34.8
and 34.15) and four negatives clones. H19 expression analysis of
both 34.15 and 34.8 clones revealed silencing of the H19 gene,
consistent with the paternal uniparental disomy (UPD) of this
locus and complete methylation of the gene in these cells. On the
contrary, methylation of IGF2-AS resulted in the variable but
significant slight induction of IGF2 compared to negative clones
(Fig. 5d).
Fig. 1 CRISPR-Cas9-mediated globin gene targeting induces Chr11p terminal deletions in HEK cells. a Experimental design. HEK293T cells edited with
Cas9 nuclease RNP and sets of gRNA corresponding to protocols #1 to #3. Map of β-globin genes, telomeric downstream SNP genes (RRM1) and FISH
probes. LOH, loss of heterozygosity; SNP, single-nucleotide polymorphism; FISH, fluorescent in situ hybridization; CGH, comparative genomic
hybridization. b Illustrative Chr11 DNA-FISH in HEK cells. Scale-bar: 5 µm. Polyclonal Chr11 DNA-FISH analysis at D4 (left) and at D18 (right) after editing
with protocols #1 to #3. NT: non-transfected. O, Orange sub-centromeric probe; G sub-telomeric Green probe. 3O/3G (in gray), 3O/2G (in red), 2O/3G
(in yellow), and 2O/2G (in black) signal percentages are quantified. 3O/2G frequencies after protocols 1–3 were compared to non-transduced cells on
same day by two-sided Chi-square tests. n correspond to analyzed cells from each polyclonal pool (1 per protocol). c left: Polyclonal Chr11 DNA-FISH
analysis at D4 after editing with protocol #3 (Chr11), without gRNA or targeting another chromosome (UROS locus in Chr10). 3O/2G frequencies targeting
Chr10 or without guide RNA were compared to protocol #3 on same day. 3O/2G frequencies targeting Chr10 or without guide RNA were compared by
two-sided Chi-square tests. Right: Polyclonal Chr11 DNA-FISH analysis at D4 after editing with protocol #3 (Chr11), and with protocol #3 using HiFi Cas9.
3O/3G, 3O/3G, 2O/3G and 2O/2G signal percentages were quantified. 3O/2G frequencies with protocol #3 using HiFi Cas9 or Cas9 were compared to
non-transduced cells by two-sided Chi-square tests. 3O/2G frequencies with protocol #3 using HiFi Cas9 were compared to protocol #3 using Cas9 by
two-sided Chi-square tests. O: orange sub-centromeric Chr11 probe, G: green sub-telomeric Chr11p probe. n correspond to analyzed cells from each
polyclonal pool (1 per protocol). Source data are provided as a Source Data file.
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Fig. 2 Confirmation and mapping of Chr11p terminal deletions. a RRM1/SNP sequencing after subclonal analysis of HEK293T at D4. C/C/G genotype in
RRM1 (in gray) on two SNP positions for NT cells. After editing, clones presented SNP-LOH with C/C (in pink) or C/G genotype (in red). Frequencies of SNP
losses are indicated in pie chart for each protocol. LOH frequencies with protocols 1–3 were compared to non-transduced cells by two-sided Chi-square tests.
Indels frequency was 63, 83 56% for protocols 1–3, respectively, n correspond to analyzed cells from each polyclonal pool (1 per protocol). b Chromosome
analysis in HEK293T clones depending on SNP screening. Left, DNA-FISH (Scale-bar: 5 µm) and array-CGH of one LOH-negative clone. Right, DNA-FISH and
array-CGH of LOH-positive clones from protocols #1–3. Deleted area is in red. n correspond to analyzed SNP loss cells (from protocols #1–3). Source data are
provided as a Source Data file.
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Discussion
In this study, we focused on the extra-large ON-target events that
may occur when using CRISPR-Cas9 nuclease in the quest to
establish appropriate quality-control measures when editing pri-
mary and animal cells. We report an ON-target genotoxicity of
CRISPR-Cas9 nuclease in HSPCs. In these clinically relevant cells,
we discovered that DNA DSB can lead in vitro to megabase-scale
iCN-LOH. We subcloned HSPSCs from four independent
transfections with protocol #3. We found 1.1% of clones (7/648)
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suggesting that these events are not so rare, considering that
millions of edited cells needed to be transplanted. While no loss
of genetic material occurs, these events should not be under-
estimated. Indeed, they may reveal recessive mutations. Cancer
cells frequently acquire a growth advantage through CN-LOH by
duplicating activating mutations in oncogenes or loosing wild-
type alleles of tumor suppressor genes in many cancers23,24
including leukemia25.
Recent literature suggests that this process could be locus and
cell type-independent. Davis et al.26 recently described CN-LOH
due to CRISPR-Cas9-mediated DSB in cancer cell lines targeting
Chr11 but at another locus 11p13 (CD44). Importantly, these
events were also observed in human-induced pluripotent stem
cells (iPSC) targeting Chr7 and Chr2114 and are still debated in
human embryos15,27. Obviously, the consequences will likely be
locus-dependent.
Here, we observed a 5.2 Mb iCN-LOH comprising 167 genes,
notably the imprinted H19 and CDKN1C (cyclin dependent
kinase inhibitor 1C) tumor suppressors and the IGF2 oncogene.
We found that HSPCs with iCN-LOH harbor a bi-allelic paternal
methylation pattern encompassing the imprinted 11p15.4-11p15.5
tumor suppressor domain, which contains the maternally
expressed CDKN1C and H19 and the paternally expressed pro-
oncogenic IGF2. CN-LOH-associated disomy of the methylated
or unmethylated alleles led to either complete inactivation or
enhanced expression of the implicated genes. Among the seven
LOH clones, three showed paternal isodisomy. The presence of a
paternal profile could be deleterious, with H19 silencing and IGF2
slight induction. Single-cell RNA-seq analysis in thousands of
clones will be informative to confirm transcriptional deregulation
of H19 and IGF2. Indeed, paternal isodisomy is a mechanism that
is known to predispose to tumors in Beckwith-Wiedemann
syndrome28. Spontaneous LOH occurs unfrequently in human
cells (<0.01%)26. The high frequency of in vitro LOH starting at
the cut-site described in this work cannot be the result of chance.
Supplementary in-vivo experiments (graft in immunodeficient
mice) will be required to evaluate (i) the graft capability of these
rearranged cells, (ii) the long-term phenotypic consequences, and
(iii) the putative selective advantage of paternal clones.
Targeting BCL11A for the induction of fetal hemoglobin29 is an
alternative therapeutic approach for hemoglobinopathies. Its
genotoxicity will need to be evaluated and compared to globin
targeting. Interestingly, there is no imprinting center downstream
of the BCL11A cleavage site and it could be safer. More generally,
in light of our results, it is important to study the cancer pre-
disposition genes distal to the DSB, notably the tumor suppressor
genes whose heterozygous inactivating mutations would initiate
or promote oncogenesis upon LOH targeting the functional allele.
We also demonstrate here that globin gene editing can induce
frequent extra-large chromosomal deletions and rare CN-LOH
in HEK cells. Our result are in accordance with previous
publications reporting the risk of chromosomal truncation in
cancer cell lines12,13. Altogether, these studies highlight a non-
locus-dependent risk. Such large-scale rearrangements with
CRISPR-Cas9 were recently described in human iPSC14 and
human embryos15. We did not succeed in isolating truncated
HSPC clones. We cannot state formally whether these
Chr11p15.4-pter deletions occurred or not. If CRISPR-induced
chromosomal deletions in HSPCs do exist, this genotoxic risk is
under 0.4%. Primary cells could not tolerate haploidy over an
extra-large region. As also suggested by three recent
papers17,18,30, we previously demonstrated that the risk of chro-
mosomal terminal deletion depends on p53 invalidation human
primary fibroblastic cells12. HSPCs could benefit from p53
activity to prevent this risk16.
Further studies will be required to evaluate whether down-
regulation or mutations of TP53 in HSPCs induce chromosomal
terminal deletion risk. It is possible that iCN-LOH is a survival
repair response to the loss of an allele in p53-proficient cells. The
mechanism of CN-LOH post CRISPR-Cas9-mediated DSB is
probably consistent with Break-induced replication (BIR) recently
described in eukaryotic cells31. It involves extensive DNA
synthesis from DSB to the telomere32 contrary to classical gene
conversion with only a short kilobase-scale patch of DNA
synthesis in the neighboring of the DSB33. DNA synthesis is
imprecise during BIR process. This unusual DNA repair pathway
can be responsible of frequent genetic instability31. A study of the
mechanisms that modulate LOH induced by CRISPR-Cas9 would
likely elucidate this issue.
In conclusion, our findings reveal an unexpected and unex-
plored form of genotoxicity that could be critical for the safety of
CRISPR-Cas9 gene therapies. These induced CN-LOHs (iCN-
LOHs) are easily missed by standard quality controls such as
locus sequencing, FISH and even array-CGH. In parallel, chro-
motrypsis has been reported as an ON-target consequence of
CRISPR-Cas9 genome editing34. The community now needs to
develop technologies without subcloning to detect all ON-target
rearrangements like CN-LOHs or megabase deletions for clinical
purposes. Future work should be aimed not only at detecting
these iCN-LOHs but also at understanding their biological roots
and reasons for occurrence as well as biological roots and phe-
notypic consequences. DSB-free genome editing with single
nickase or base editors or nuclease-based gene therapy in iPSC
with safe corrected clone sorting might be answers35–37.
Methods
Cell culture. Human embryonic kidney (HEK) cell line HEK293T (ATCC, Man-
assas, VA, USA) was maintained in Dulbecco’s modified Eagle’s medium (DMEM),
low glucose (1G.L-1), L-glutamine (1G.L-1) and pyruvate (Gibco by Life-
technologiesTM, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum,
100 U/mL penicillin, and 100 μg/mL streptomycin (all from EurobioTM, Courta-
boeuf, France). Human CD34+ HSPCs were isolated from the cord blood of
healthy donors from Bagatelle Hospital, Bordeaux, France, according to the ethical
Fig. 3 CRISPR-Cas9-mediated globin gene targeting can induce Chr11p copy-neutral-LOH (iCN-LOH) in HSPC. a Experimental design human CD34+
from cord blood edited with Cas9 RNP and sets of gRNA corresponding to protocols #1 and #3. Map of β-globin genes, telomeric downstream SNP genes
(RRM1, CARS1 and KCNQ1), telomeric imprinted genes (H19 and IGF2) and FISH probes. b Top panel illustrative Chr11 DNA-FISH in hCD34+ cells. Scale-bar:
5 µm. Bottom panel, polyclonal Chr11 DNA-FISH analysis at D18 of edited cells with protocols #1 (left) and #3 (right). Median of each Chr11 profile (2O/2G
(in gray), 2O/1G (in green), 1O/2G (in orange)) in non-transfected cells as control (NT, Non-Transfected) and edited cells with protocols #1 and #3 (n=
7). O: orange sub-centromeric Chr11 probe, G: green sub-telomeric Chr11p probe. 2O/1G frequencies were compared between conditions by two-sided Chi-
square tests. n correspond to analyzed hCD34+ cells for each protocol (pooled from three distinct transfections). c Polyclonal Chr2 DNA-FISH analysis at
day 18 of edited cells (in Chr11) with protocol #3 or non-transfected cells. O: orange sub-telomeric Chr2 probe, G: green sub-centromeric Chr2 probe. 2G/
1O (in orange) frequencies were compared between conditions by two-sided Chi-square tests. n correspond to analyzed hCD34+ cells for each protocol.
d RRM1/CARS1 SNPs sequencing after subclonal analysis of CD34+ cells at D4, illustrating SNP-LOH observed in clones 34.8 and 34.15 from protocols
#3.1 and #3.2. e Chromosome analysis of two HSPC clones with LOH by array-CGH (34.8 and 34.15). f LOH-positive clone frequencies for protocols #1,
#3.1 and #3.2. Source data are provided as a Source Data file.
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Institutional review board of Bagatelle Hospital, (Maison de Santé Protestante de
Bordeaux Talence FRANCE) and with the mother’s informed consent. Briefly,
mononuclear cells were isolated by Ficoll gradient. CD34+ cells were purified
according to the manufacturer’s instructions (Human CD34-Positive Selection kit
II ref 17865 from Stem Cell Technologies) and purity was analyzed by flow
cytometry using phycoerythrin-conjugated anti-CD34 antibody (clone 561 Biole-
gend (San Diego CA, USA) 25 μg/mL lot # B2044487 5 μL/test). Cryopreserved
CD34+ cells were thawed and cultured in expansion medium consisting in Stem
Span SFEM (Stem Cell Technologies) supplemented with Flt3-L (50 ng/mL), SCF
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Fig. 4 CD34+ LOH clone presence is not dependent of VPA and enhancer. a LOH-positive clone frequencies in experiments with or without valproic acid
(VPA) and transfection enhancer (enh). b Illustrative Sanger sequencing of 2 RRM1 SNPs at 1.1 Mb from the cut-site (rs4910888 and rs4910889) and
KCNQ1 SNP at 2.5Mb from the cut-site (rs231357). c Allele-specific qPCR of RRM1 (rs4910889) to determine presence or absence of SNP with illustrative
curves (low panel). Non-transduced CD34+ (NT), clone 34.2 and 34.286 without LOH are heterozygous with T/C alleles (allele C in blue and allele T in
red). Presence of single allele revealed LOH in numerous clones. NTC, No template control. Source data are provided as a Source Data file.
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ng/mL) (all from Peprotech), StemRegenin 1 (SR1) (1 μM) (Stem Cell Technolo-
gies), VPA valproic acid (500 µM) (Sigma-Aldrich) (that stimulates proliferation
and pluripotency of HSPC)38 and 100 U/mL penicillin, and 100 μg/mL strepto-
mycin (Eurobio). Both cells were cultured at 37 °C and with 5% CO2 in a humi-
dified chamber. Two days after thawing CD34+ cells were transfected with Cas9
RNP (see below). For cellular clonal analysis, transfected cells were isolated and
sorted by BD FACS Aria 4 days after transfection. They were cultured onto 96-well
plates (Corning©, Tewksbury, MA, USA) and cultured as described above (cloning
efficiency 50%). SNP screening analysis was performed 3 weeks after subcloning.
SNP-analyses and methylation required at least 2 months expansion (clones 34.8
and 34.15). For the #3.4 experiment, CD34+ cells were plated in 35-mm tissue
culture dishes at 150 and 450 cells/mL with 1 mL of methylcellulose medium
(Stemcell Technologies, MethoCult H4034 Optimum) and cultured at 37 °C in a
humidified atmosphere containing 5% CO2. After 10 days, individual colonies were
subsequently picked from plates and washed in PBS to remove all the methylcel-
lulose. Cells were digested with proteinase K in lysis buffer (10 mmol/L Tris–Cl, pH
Unmethylated alleles
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8.0, 50 mmol/L KCl, 2.5 mmol/L MgCl2, 0.5% Tween 20, 100 mg/mL proteinase K)
at 56 °C for 2 h, followed by a 10-min exposure at 95 °C.
Editing tools. HEK-293T and CD34+ cells were transfected by electroporation
using the 4D-Nucleofector system AMAXA (Lonza®, Bale, Switzerland) with SF
Cell Line 4D-Nucleofector® in association with the DG-150 program and the DO-
100 program, respectively, according to the manufacturer’s instructions. To form
RNP complex, Cas9 protein was complexed to crRNA:tracrRNA according to the
manufacturer’s instructions. Then, complexes were incubated for 20 min at room
temperature before electroporation. Cas9 protein (Alt-R® S.p. Cas9 Nuclease V3 or
HiFi Cas9 V3 nuclease) and crRNA (Alt-R® CRISPR-Cas9 crRNA) were purchased
from Integrated DNA Technologies (IDT, Coralville, IA, USA). Briefly, 106
HEK293T cells or 150,000 primary CD34+ cells were nucleofected with 17 µg of
nuclease-Cas9/cr/Tracr RNA complex (RNP) and 5 µM of Alt-R® Cas9 Electro-
poration Enhancer. Cells were then seeded onto 6-well plates (Corning©, Tewks-
bury, MA, USA) and cultured as described above.
SNP analysis by Sanger sequencing and allele-specific quantitative PCR. We
used dbSNP (NCBI, nih.gov) to screen frequent SNPs in telomeric location from
the beta-globin locus. We selected and tested SNPs in RRM1, CARS1 and KCNQ1
to suspect or confirm Chr11p LOH. We recovered five SNPs from SNP-array data
in telomeric location from the beta-globin locus to confirm Chr11p LOH SNP-
array results (Supplementary Fig. 8) and 2 framing the globin cut-site (Supple-
mentary Fig. 9). Genomic DNA was extracted for each clone by using Nucleospin®
Tissue (Macherey-Nagel, Duren, Germany) according to the manufacturer’s pro-
tocol. The genomic regions flanking SNPs were amplified by PCR (HotStarTaq
Plus DNA polymerase, Qiagen®, Venlo, Netherlands) with adequate primers
(Supplementary Table 5). Design of primer was made using Primer-BLAST web
tool (Primer designing tool (nih.gov).). The primer annealing temperature was
calculated with a Tm calculator from New England Biolabs NEB (Tm Calculator
v1.13.0; https://tmcalculator.neb.com/#!/main). PCR products were purified with
Nucleospin® Gel and PCR Clean-up (Macherey-Nagel) and sequenced. Alter-
natively, SNP genotyping was also performed by real-time quantitative PCR ana-
lysis (CFX Connect device, Biorad®) of genomic DNA with a common reverse
primer and SNP allele-specific forward primers (the 3′ end nucleotide in bold is
allele-specific, the underlined nucleotide in italic being a deliberate C/T mismatch
introduced to enhance specificity). SNP rs4910889 primers, RRM1 gene (locus
11p15.4): Forward primer allele T: CCTGAGTGCCACAGTCCCAGT; Forward
primer allele C: CTGAGTGCCACAGTCCCAGC; Common reverse primer:
AGGCAATTCCACAGTATGGGT. SNP rs231357 primers, KCNQ1/KCNQ1OT1
gene (locus 11p15.5-p15.4): Forward primer allele A: ACGTTTCATAGTCAGAC
AAACCCA; Forward primer allele G: CGTTTCATAGTCAGACAAACCCG;
Common reverse primer: GGGGAGGATGAAGTTAGCTGA. To validate these
real-time PCR assays, PCR was performed in parallel with flanking primers
encompassing the SNPs of interest, and PCR products were processed by Sanger
sequencing. Quantitative allele-specific PCR analyses were quantified using the
comparative MNE (Mean Normalized Expression) method,39.
ICE analysis of outcome of INDELs. Genomic DNA was extracted using
Nucleospin® Tissue (Macherey-Nagel, Duren, Germany) according to the manu-
facturer’s protocol. The genomic region flanking HBB exon 1, HBG2 and HBG1
promoter, and the 5′ breakpoint of the Corfu deletion were amplified by PCR
(HotStarTaq Plus DNA polymerase, Qiagen®, Venlo, Netherlands) with adequate
primers (Supplementary Table 4). PCR products were purified with Nucleospin®
Gel and PCR Clean-up (Macherey-Nagel) and sequenced (LIGHTRUN, GATC
Biotech, Konstanz, Germany). The Inference of CRISPR Editing (ICE) software
(https://ice.synthego.com) was used to determine the percentage of indels among
polyclonal populations for all protocols allowing gRNA efficiencies by ICE
(Synthego). Non-transfected HEK293T and primary CD34+ cells are provided as
control chromatogram. The limit of quantification (loq) was set at 2%.
Cytogenetic examination of chromosomes 11 and 2. To validate the SNP loss
screening method and visualize chromosomal instability, FISH was performed on
interphase nuclei with probes targeting the following regions on Chr11: sub-
centromeric region (XCE 11 probe, labeled in orange) (MetaSystems Probes,
Altlussheim, Germany), and sub-telomeric regions (p-arm sub-telomere probes
labeled in green) (Cytocell Ltd, Cambridge, UK). In parallel, Chr2 was analyzed by
FISH as control. FISH was performed on interphase nuclei with probes targeting
the following regions on Chr2: sub-centromeric region (XCE 2 probe, labeled in
green) (MetaSystems Probes, Altlussheim, Germany), and sub-telomeric regions
(q-arm sub-telomere probes labeled in red (Texas red)) (Cytocell Ltd,
Cambridge, UK).
Preparations were pre-treated as indicated below. Briefly, cells were first lysed
by hypotonic shock using a 2.8G/L KCl solution, then fixed using a ¾ methanol
¼ acetic acid solution and deposited onto Super Frost microscopy slides
(Thermo Scientific™). The slides were successively immersed in a 2x saline-
sodium citrate buffer for 10 min at 37 °C, in a 0.01% pepsin solution for 10 min
at 37 °С, in a 1x phosphate-buffered saline (PBS) solution for 5 min, in a 3.7%
formaldehyde solution for 5 min, and finally in a 1x PBS solution for 5 min.
Then they were dehydrated by immersing them successively for 1 min in four
coplins of alcohol 70°, 80°, 90°, and 100°. FISH probes and DNA were then
co-denaturated according to the manufacturers’ protocols, and hybridization
was performed overnight at 37 °C. The slides were then immersed successively in
wash solutions and the nucleic acids were counterstained by 4,6-diamidino-2-
phenylindole (DAPI). The slides were then placed under an Axio Imager-2
microscope with an epi-fluorescence source (Carl Zeiss AG, Oberkochen,
Germany). The microscope was linked to the Metafer 4 software for automated
image acquisition and processing (MetaSystems GmbH, Altlussheim, Germany).
Magnification factor X630.
Array-CGH and SNP array. Array-CGH was performed on 8x60k oligonucleotide
microarrays, SNP+ CGH Array was performed on Genetisure Cyto 180 K CGH/
SNP arrays (Agilent Technologies, CA). DNA was labeled (cyanine 3 or cyanine 5)
using the Genomic DNA ULS Labeling Kit from Agilent Technologies and
hybridized onto the microarrays according to the manufacturer’s instructions
(Agilent).For SNP+ CGH arrays, tested DNAs were hybridized against male
control DNA obtained from Agilent. Scanning of the microarrays was performed
using a G2565CA scanner (Agilent). Data analysis was carried out with Agilent
Technologies software, namely Feature Extraction for Cytogenomics Algorithm
V5.0.1.16 for the fluorescence ratio calculation and Agilent CytoGenomics 4.0 and
5.0 to visualize chromosomal imbalances and loss of heterozygosity (LOH).
Deletions and duplications in the heterozygous state were characterized by values
of the log2 ratio of fluorescence intensities (cyanine 5/cyanine 3) below −0.5 and
above +0.3, respectively, with the statistical algorithm ADM2 used at a threshold of
5. LOH was evaluated with the statistical algorithm ADM2 used at a threshold of 6
(Default Analysis Method v2).
Off-target analysis. The Top-10-predicted off-target sites identified by CRISPOR
software were screened to evaluate a putative off-target in Chr11 (Supplementary
Table 2).
Methylation analyses. Bisulfite conversion of 250 ng of genomic DNA was per-
formed using the EpiTect Bisulfite Kit according to the manufacturer’s instructions
(QIAGEN, Hilden, Germany). Methylation was then analyzed using real-time
quantitative methylation-specific PCR (qMSP)39. Real-time quantitative PCR
Fig. 5 CRISPR-Cas9-Induced Chr11p copy-neutral-LOH (iCN-LOH) impacts methylation of imprinting centers and imprinted genes expression in
HSPCs. a CGH/SNP-array: Log2Ratio and BAF (B-allele frequency) in control-HSPC cells and two edited LOH-positive-clones, zoomed on Chr11p15. Globin
cut-site location is indicated by a black line. RRM1 and CARS SNP losses are indicated by a blue line. LOH are framed. b Percentages of unmethylated and
methylated alleles of H19 differentially methylated region (H19 DMR), H19 gene proximal promoter and KCNQ1OT1 (KCNQ1 opposite strand/antisense
transcript 1) in NT-CD34+ (non-transduced parental CD34+ cells), in five edited clones without LOH (34.11, 34.13, 34.33, 34.36, 34.80), in a pool of
negative LOH edited clones, in 3 clones with LOH (34.8, 34.15 and 34.40) analyzed by quantitative real-time methylation-specific PCR (qMSP). in vitro
methylated DNA and No DNA (NTC) were used as positive and negative controls. ND: non determined because of lack of DNA cell material. c Diagram of
Chr11p15.4-p15.5 band with position of imprinted genes and CRISPR-Cas9-induced DNA-DSB (red arrow) in HSPCs. Paternal and maternal alleles in light
blue and pink, respectively. Unmethylated and methylated CpG islands represented by white and black circles. Genes expressed from parental allele in dark
blue, gene silenced on parental allele in red. Normal paternal and maternal allele from NT-CD34+ cells and alleles from paternal and maternal iCN-LOH
clones are represented. d H19 and IGF2 mRNA expression in NT-CD34+ cells, in four edited LOH-negative clones (34.4, 34.17, 34.80, and 34.96) and two
LOH-positive clones (34.8 and 34.15). Results are normalized using TATA-box binding protein (TBP) housekeeping gene. LOD, limit of detection.
Quantification is represented by mean and SEM from the same sample measured repeatedly. H19mRNA is not or hardly detectable in LOH-positive clones.
IGF2 mRNA is only detectable in LOH-positive clones. Source data are provided as a Source Data file.
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amplification conditions were 95 °C for 3 min, followed by 45 cycles at 95 °C for
30 s, 62 °C for 30 s, and 66 °C for 30 s, using a SyberGreen Master Mix (ROCHE
Molecular Diagnostics), and a LC480 qPCR machine (ROCHE Molecular Diag-
nostics). The primers used for qMSP and BGS analyses were designed using the
MethPrimer website [https://www.urogene.org/cgi-bin/methprimer/methprimer.
cgi] and the OLIGO 4.0 software (Molecular Biology Insights, Inc., Colorado
Springs, CO, USA). Primer sequences for the H19 proximal promoter were:
Methylated alleles: Forward: CGTTTGTTAGTAGAGTGCGTTCG, Reverse: AAC
CGAACTTATACTCGTCACCG; Unmethylated alleles: Forward: TATTGTTTGT
TAGTAGAGTGTGTTTG, Reverse: ATTAACCAAACTTATACTCATCACCA.
Primer sequences for the H19 DMR (differentially methylated region) were:
Methylated alleles: Forward: CGGTTTTATCGTTTGGATGGTAC, Reverse: CGA
CGCGTAACTTAAATAACCCG; Unmethylated alleles: Forward: TTTTGGTTTT
ATTGTTTGGATGGTAT, Reverse: CTACAACACATAACTTAAATAACCCA.
Primer sequences for the IGF2 DMR (differentially methylated region) were:
Methylated alleles: Forward: ATTTTTTTAGGAAGTATAGTTACGTC, Reverse:
ATAAAAAATACACACGAATAACCCG; Unmethylated alleles: Forward: TTT
ATTTTTTTAGGAAGTATAGTTATGTT, Reverse: AAATAAAAAATACACACA
AATAACCCA. Primer sequences for the KCNQ1OT1 (KCNQ1 opposite strand/
antisense transcript 1) DMR (differentially methylated region) were: Methylated
alleles: Forward: GTTTATTATTTCGGGGTGATCGC, Reverse: CTAATCTCGAA
CGTAACCTAAACG; Unmethylated alleles: Forward: GTGTTTATTATTTTGGG
GTGATTGT, Reverse: AACTAATCTCAAACATAACCTAAACA. Quantitative
methylation-specific PCR (qMSP) analyses were quantified using the comparative
MNE (mean normalized expression) method39, here adapted to copy numbers of
unmethylated and methylated DNA alleles. Data are displayed as percentage of
unmethylated and methylated alleles. PCR specificity was verified by melting
curves, gel electrophoresis and Sanger sequencing analyses.
DNA from wild-type CD34+ cells and CRISPR-Cas9 clones 34.8 and 34.15 with
iCN-LOH were analyzed by quantitative real-time methylation-specific PCR
(qMSP). Wild-type peripheral blood leukocytes (PBL) from healthy donors, in vitro
methylated DNA and No DNA were used as negative and positive controls.
Percentages of unmethylated and methylated alleles (mean ± SEM from
independent measurements) are shown.
Gene expression analysis. Gene expression levels were determined by
reverse transcription/real-time quantitative PCR (qRT-PCR), using the compara-
tive MNE (Mean Normalized Expression) method40. The primers used for qRT-
PCR analyses were H19-forward: CGTCCCTTCTGAATTTAATTTG, H19-reverse:
ACACTCGTACTGAGACTC, IGF2- forward: GTCGCAGCCGTGGCATCGTT,
IGF2-reverse: AGGTGTCATATTGGAAGAACTTG. To normalize the qRT-PCR
data, we used the primers for the following housekeeping genes: TATA box binding
protein (TBP): TBP-forward: AGTGAAGAACAGTCCAGACTG, TBP-reverse:
CCAGGAAATAACTCTGGCTCAT; Glyceraldehyde-3-phosphate dehydrogenase
(GAPDH): GAPDH-forward: CTGCACCACCAACTGCTTAG, GAPDH-reverse:
AGGTCCACCACTGACACGTT; and eukaryotic translation elongation factor 1
alpha 1 (EEF1A1/EF1α): EF1α-forward: CTGGAGCCAAGTGCTAACATG, EF1α-
reverse: CCGGGTTTGAGAACACCAGT. Similar results were obtained when
normalizing with these three housekeeping genes. Melting curves, gel electro-
phoresis and sequencing analyses showed that these primers amplified only the
specific fragments.
Statistical analysis. Statistical significance was inferred when necessary. Graph
Pad Prism 6 software was used for statistical analysis. Results are presented as
mean ± SEM (standard error of the mean). Two-sided chi-squared tests were used
to compare percentages. All comparisons are shown with black bars. Null
hypothesis was rejected when p-value < 0.05. ns, non-significant.
Reporting summary. Further information on research design is available in the Nature
Research Reporting Summary linked to this article.
Data availability
The source data generated in this study have been deposited in the ZENODO database
https://doi.org/10.5281/zenodo.5130579.
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